Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.

12 May 2010

Periodontal disease treatment reduces blood sugar levels in Type 2 diabetes patients

A study to be published in the latest issue of The Cochrane Library and led by researchers at the University of Edinburgh and supported by colleagues at the Peninsula Dental School, the University of Ottawa and UCL Eastman Dental Institute, suggests that the treatment of serious gum (periodontal) disease in diabetics with Type 2 diabetes may lower their blood sugar levels.

12 May 2010

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes: Researchers

Routine dental treatment can reduce blood glucose levels in people with type 2 diabetes who have preexisting gum disease.

12 May 2010

Overtime workers at 60% higher risk of heart-related problems

Working overtime is bad for the heart according to results from a long-running study following more than 10,000 civil servants in London (UK): the Whitehall II study.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

People with family history of diabetes gain more weight

In the first study of its type, Australian researchers have shown that healthy people with a genetic predisposition to Type 2 diabetes gain more weight overeating over the short term than their non-genetically-prone counterparts.

11 May 2010

Genetic link to risk for diabetes and weight gain: New study

A recent study published in the international journal Diabetologia showed that Australians who eat too many high fat snacks tend to put on more weight if they have someone in their family with diabetes.

10 May 2010

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor Biosciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released an update to its development program for Triolex to treat obesity-induced insulin resistance and type-2 diabetes mellitus (T2DM).

10 May 2010

Lexicon Pharmaceuticals first-quarter revenues down 61%

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2010.

10 May 2010

Negative impact of depression on glycemic control in type 2 diabetes patients

In this German prospective representative study of patients with type 2 diabetes, baseline depression predicted problems with medication adherence, problems with health-related behaviors, and unsatisfactory glycemic control at follow-up.

10 May 2010

Insulin can help reduce risk of type 2 diabetes

Recent decades have seen a huge increase in type 2 diabetes and cardiovascular disease. This is a result of people being less active and eating fattier diets, which can lead to obesity and, in turn, diabetes.

10 May 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

7 May 2010

Peptides: A new clue on the origins of life

Emory University scientists have discovered that simple peptides can organize into bi-layer membranes. The finding suggests a "missing link" between the pre-biotic Earth's chemical inventory and the organizational scaffolding essential to life.

7 May 2010

A checklist to stay healthy at every age

Shantanu Nundy, MD, a second-year resident in internal medicine at the University of Chicago Medical Center may soon find out. Driven by his mother's health questions and the difficulty of providing simple, reliable answers, Nundy collected all of the "generally accepted truths" about preventing disease, organized them into checklists based on age, and persuaded the Johns Hopkins University Press to publish them as Stay Healthy at Every Age: What Your Doctor Wants you to Know.

7 May 2010

Imprinted genes may be the root cause of gender specific diseases, says study

Pregnancy places competing demands on a mother's physiology: Her body wants to produce a strong healthy baby but not at the expense of her own health. Some of the genes that she passes on to her child therefore try to protect her own body from excessive demands from her child.

7 May 2010

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801.

7 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

New study shows single night of partial sleep deprivation can induce insulin resistance

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, just one night of short sleep duration can induce insulin resistance, a component of type 2 diabetes.

6 May 2010

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Osiris Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 May 2010